Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial

Lourdes Cabrera-García, Sara Cruz-Melguizo, Belén Ruiz-Antorán, Ferrán Torres, Ana Velasco, Cristina Martínez-Payo, Cristina Avendaño-Solá, PESAPRO trial Group, Lourdes Cabrera-García, Sara Cruz-Melguizo, Belén Ruiz-Antorán, Ferrán Torres, Ana Velasco, Cristina Martínez-Payo, Cristina Avendaño-Solá, PESAPRO trial Group

Abstract

Background: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another.

Methods/design: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015.

Discussion: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations.

Trial registration: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012); ClinicalTrials.gov Identifier NCT01643980 (Date of registration: 12 June 2012).

References

    1. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med. 1996;334:567–72. doi: 10.1056/NEJM199602293340904.
    1. Honest H, Bachmann LM, Coomarasamy A, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervical transvaginal sonography in predicting preterm birth: a systematic review. Ultrasound Obstet Gynecol. 2003;22:305–22. doi: 10.1002/uog.202.
    1. Celik E, To M, Gajewska K, Smith GC, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound Obstet Gynecol. 2008;31:549–54. doi: 10.1002/uog.5333.
    1. Morken NH. Preterm birth: new data on a global health priority. Lancet. 2012;379:2128–30. doi: 10.1016/S0140-6736(12)60857-5.
    1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75–84. doi: 10.1016/S0140-6736(08)60074-4.
    1. Petrou S. Economic consequences of preterm birth and low birthweight. BJOG. 2003;110(Suppl 20):17–23. doi: 10.1046/j.1471-0528.2003.00013.x.
    1. del Instituto de Información Sanitaria. Ministerio de Sanidad, Servicios Sociales e Igualdad. Datos GRD 2009. . Accessed 03 Nov 2011.
    1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162–72. doi: 10.1016/S0140-6736(12)60820-4.
    1. Crane JM, Hutchens D. Transvaginal sonographic measurement of cervical length to predict preterm birth in asymptomatic women at increased risk: a systematic review. Ultrasound Obstet Gynecol. 2008;31:579–87. doi: 10.1002/uog.5323.
    1. Matijevic R, Grgic O, Vasilj O. Is sonographic assessment of cervical length better than digital examination in screening for preterm delivery in a low-risk population? Acta Obstet Gynecol Scand. 2006;85:1342–7. doi: 10.1080/00016340600935722.
    1. Owen J, Yost N, Berghella V, Thom E, Swain M, Dildy GA, et al. Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth. JAMA. 2001;286:1340–8. doi: 10.1001/jama.286.11.1340.
    1. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol. 2006;27:362–7. doi: 10.1002/uog.2773.
    1. Owen J. Evaluation of the cervix by ultrasound for the prediction of preterm birth. Clin Perinatol. 2003;30:735–55. doi: 10.1016/S0095-5108(03)00103-9.
    1. Berghella V, Baxter JK, Hendrix NW. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane Database Syst Rev. 2009;3
    1. Lim K, Butt K, Crane JM. SOGC Clinical Practice Guideline. Ultrasonographic cervical length assessment in predicting preterm birth in singleton pregnancies. J Obstet Gynaecol Can. 2011;33:486–99.
    1. RANZCOG College Statement C-Obs 27: Measurement of cervical length for prediction of preterm birth. 2008. . Accessed 10 May 2011.
    1. Committee on Practice Bulletins—Obstetrics. The American College of Obstetricians and Gynecologists Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964–73. doi: 10.1097/AOG.0b013e3182723b1b.
    1. Iams JD, Romero R, Culhane JF, Goldenberg RL. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet. 2008;371:164–75. doi: 10.1016/S0140-6736(08)60108-7.
    1. Piso B, Zechmeister-Koss I, Winkler R. Antenatal interventions to reduce preterm birth: an overview of Cochrane Systematic Reviews. BMC Res Notes. 2014;7:265. doi: 10.1186/1756-0500-7-265.
    1. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18–31. doi: 10.1002/uog.9017.
    1. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462–9. doi: 10.1056/NEJMoa067815.
    1. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;5:697–705. doi: 10.1002/uog.5159.
    1. Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA, et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol. 2010;202:548. doi: 10.1016/j.ajog.2009.12.012.
    1. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30(5):687–96. doi: 10.1002/uog.5158.
    1. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol. 2009;200:219–24. doi: 10.1016/j.ajog.2008.12.035.
    1. Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol. 2008;112:127–34. doi: 10.1097/AOG.0b013e31817d0262.
    1. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206:124. doi: 10.1016/j.ajog.2012.03.008.
    1. Farine D, Mundle WR, Dodd J, Basso M, Delisle MF, Grabowska K, et al. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can. 2008;30:67–77.
    1. Arabin B, Halbesma JR, Vork F, Hübener M, van Eyck J. Is treatment with vaginal pessaries an option in patients with a sonographically detected short cervix? J Perinat Med. 2003;31:122–33. doi: 10.1515/JPM.2003.017.
    1. Goya M, Pratcorona L, Merced C, Rodó C, Valle L, Romero A, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet. 2012;379:1800–6. doi: 10.1016/S0140-6736(12)60030-0.
    1. Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA. Cervical pessary for preventing preterm birth. Cochrane Database Syst Rev. 2013;5
    1. Liem SM, van Pampus MG, Mol BW, Bekedam DJ. Cervical pessaries for the prevention of preterm birth: a systematic review. Obstet Gynecol Int. 2013;2013:576723.
    1. Acharya G, Eschler B, Grønberg M, Hentemann M, Ottersen T, Maltau JM. Noninvasive cerclage for the management of cervical incompetence: a prospective study. Arch Gynecol Obstet. 2006;273:283–7. doi: 10.1007/s00404-005-0082-2.
    1. Kimber-Trojnar Z, Patro-Małysza J, Leszczyńska-Gorzelak B, Marciniak B, Oleszczuk J. Pessary use for the treatment of cervical incompetence and prevention of preterm labour. J Matern Fetal Neonatal Med. 2010;23:1493–9. doi: 10.3109/14767051003678093.
    1. Newcomer J. Pessaries for the treatment of incompetent cervix and premature delivery. Obstet Gynecol Surv. 2000;55:443–8. doi: 10.1097/00006254-200007000-00023.
    1. AEMPS. S.A.o.M.P. Monograph Product Progefik (progesterone). S.A.o.M. Products, Editor. 2010. . Accessed 10 Oct 2011
    1. Alfirevic Z, Owen J, Carreras Moratonas E, Sharp AN, Szychowski JM, Goya M. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. Ultrasound Obstet Gynecol. 2013;41:146–51. doi: 10.1002/uog.12300.
    1. To MS, Skentou C, Chan C, Zagaliki A, Nicolaides KH. Cervical assessment at the routine 23-week scan: standardizing techniques. Ultrasound Obstet Gynecol. 2001;17:217–9. doi: 10.1046/j.1469-0705.2001.00369.x.
    1. Heath VC, Souka AP, Erasmus I, Gibb DM, Nicolaides KH. Cervical length at 23 weeks of gestation: the value of Shirodkar suture for the short cervix. Ultrasound Obstet Gynecol. 1998;12:318–22. doi: 10.1046/j.1469-0705.1998.12050318.x.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する